Aurobindo Pharma gains after reporting decent Q1 numbers

Image
Capital Market
Last Updated : Aug 13 2015 | 11:33 AM IST

Aurobindo Pharma rose 3.09% to Rs 767.20 at 10:31 IST on BSE after consolidated net profit rose 4.1% to Rs 432.40 crore on 14.1% growth in net operating income to Rs 3320.40 crore in Q1 June 2015 over Q1 June 2014.

The Q1 result was announced after market hours yesterday, 12 August 2015.

Meanwhile, the S&P BSE Sensex was up 118.62 points or 0.43% at 27,630.88.

On BSE, so far 2.21 lakh shares were traded in the counter as against average daily volume of 1.46 lakh shares in the past one quarter.

The stock hit a high of Rs 777 and a low of Rs 750 so far during the day. The stock had hit record high of Rs 796 on 7 August 2015. The stock had hit 52-week low of Rs 375.88 on 13 August 2014.

The stock had outperformed the market over the past one month till 12 August 2015, advancing 2.46% compared with Sensex's 0.54% fall. The scrip had also outperformed the market in past one quarter, surging 12.58% as against Sensex's 2.36% rise.

The large-cap pharma company has equity capital of Rs 58.40 crore. Face value per share is Re 1.

Aurobindo Pharma's sales from Formulations business rose 15.9% to Rs 2637.10 crore in Q1 June 2015 over Q1 June 2014. Sales from active pharmaceutical ingredients (APIs) business rose 7.9% to Rs 723 crore in Q1 June 2015 over Q1 June 2014.

Aurobindo Pharma, headquartered at Hyderabad, manufactures generic pharmaceuticals and active pharmaceutical ingredients.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 13 2015 | 10:32 AM IST

Next Story